Identification of novel candidate genes and predicted miRNAs in atopic dermatitis patients by bioinformatic methods

被引:0
作者
LiangHong Chen
Xin Qi
JingYu Wang
JiaLi Yin
PeiHong Sun
Yan Sun
Yan Wu
Li Zhang
XingHua Gao
机构
[1] The First Hospital of China Medical University,Department of Dermatology
[2] Shengjing Hospital of China Medical University,Department of Emergency Medicine
[3] Ministry of Education and NHC,Key Laboratory of Immunodermatology
[4] National Joint Engineering Research Center for Theranostics of Immunological Skin Diseases,undefined
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Atopic dermatitis (AD) is a common, chronic inflammatory dermatosis with relapsing eruptions. Our study used bioinformatics to find novel candidate differentially expressed genes (DEGs) and predicted miRNAs between AD patients and healthy controls. The Mesh term “atopic dermatitis” was retrieved to obtain DEGs in GEO datasets. DEGs between AD patients and healthy controls were analyzed using GEO2R. Overlapping DEGs between different datasets were obtained with use of Draw Venn software. GO and KEGG enrichment analyses were conducted by the use of DAVID. STRING and miRWalk were used to individually analyze PPI networks, interactions of candidate genes and predicted miRNAs. A total of 571 skin samples, as retrieved from 9 databases were assessed. There were 225 overlapping DEGs between lesioned skin samples of AD patients and that of healthy controls. Nineteen nodes and 160 edges were found in the largest PPI cluster, consisting of 17 up-regulated and 2 down-regulated nodes. Two KEGG pathways were identified, including the cell cycle (CCNB1, CHEK1, BUB1B, MCM5) and p53 (CCNB1, CHEK1, GTSE1) pathways. There were 56 nodes and 100 edges obtained in the miRNA-target gene network, with has-miR-17-5p targeted to 4 genes and has-miR-106b-5p targeted to 3 genes. While these findings will require further verification as achieved with experiments involving in vivo and in vitro modles, these results provided some initial insights into dysfunctional inflammatory and immune responses associated with AD. Such information offers the potential to develop novel therapeutic targets for use in preventing and treating AD.
引用
收藏
相关论文
共 249 条
[1]  
Willems A(2021)Prevalence and associations of general practice registrars’ management of atopic dermatitis: A cross-sectional analysis from the registrar clinical encounters in training study Dermatol Pract Concept. 11 e2021128-30
[2]  
Tapley A(2022)Keratinocytes: An enigmatic factor in atopic dermatitis Cells 11 1683-2177
[3]  
Fielding A(2022)Exacerbating factors and disease burden in patients with atopic dermatitis Allergol. Int. 71 25-638
[4]  
Tng ETV(2021)The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019 World Allergy Organ. J. 14 100604-1155
[5]  
Holliday EG(2021)Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors Allergol. Int. 19 622-43
[6]  
van Driel ML(2021)Echinochrome A Treatment alleviates atopic dermatitis-like skin lesions in NC/Nga mice via IL-4 and IL-13 suppression Mar. Drugs 53 2165-39
[7]  
Das P(2021)Dermatology for the internist: Optimal diagnosis and management of atopic dermatitis Ann. Med. 22 625-526
[8]  
Mounika P(2021)Tralokinumab for the treatment of atopic dermatitis Am. J. Clin. Dermatol. 30 1150-40
[9]  
Yellurkar ML(2021)Current understanding of epigenetics in atopic dermatitis Exp. Dermatol. 124 36-11
[10]  
Prasanna VS(2020)Liquid-liquid phase separation drives skin barrier formation Science 8 326-140